The Role of 5-Alpha-Reductase Inhibitors in Active Surveillance

    March 2012 in “ Current opinion in urology ”
    David Margel, Neil Fleshner
    Studysummary This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. The Risks and Benefits of 5α-Reductase Inhibitors for Prostate Cancer Prevention New England journal of medicine/˜The œNew England journal of medicine · 2011
    2. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004